Tools to prioritize outpatients for pharmaceutical service: A scoping review

Sousa, Maria do Carmo Vilas Boas; Fernandes, Brígida Dias; Foppa, Aline Aparecida; Almeida, Paulo Henrique Ribeiro Fernandes; Mendonça, Simone de Araújo Medina; Chemello, Clarice

doi:10.1016/j.sapharm.2020.02.010

Cited by 11 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, no validated tool is available to reliably assist GPs in prioritizing the patients at the greatest risk of DRPs to receive a CMR 25 . A recent review identified 13 studies involving tools to prioritize patients for pharmaceutical services in the outpatient setting 25 .…”

Section: Discussionmentioning

confidence: 99%

“…[21][22][23][24] However, only few tools have been developed in primary care, and routine use is limited due to insufficient performance and lack of validation. 25 In the Danish hospital setting, a generic diagnostic model, the Medication Risk Score (MERIS), was recently developed. 26 The purpose of the MERIS was to stratify patients into groups at risk of potentially serious DRPs according to the criteria developed by the World Health Organisation (WHO) 27 as a means of prioritizing patients in most need of a CMR.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drug‐related problems

Høj

Pedersen²,

Lundberg

et al. 2021

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Drug-related problems are important causes of patient harm and increased healthcare costs. To assist general practitioners in prioritizing patients in need of a critical medication review, we aimed to assess the ability of the Medication Risk Score (MERIS) to stratify patients with polypharmacy in general practice according to their risk of drug-related problems. We conducted a crosssectional multi-centre external validation study. Patients receiving more than five concomitant medications (polypharmacy) were eligible. The outcome was potentially serious drug-related problems as evaluated by expert consensus.Performance was assessed in terms of calibration and discrimination indices. Of 497 patients, 489 were included in the main analysis. The median age

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drug‐related problems

Høj

Pedersen²,

Lundberg

et al. 2021

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Nesta etapa, os autores do presente estudo optaram por selecionar dois artigosuma revisão sistemática e uma revisão de escopo -que dizem respeito à mesma temática para viabilizar a comparação dos aspectos metodológicos utilizados entre as revisões. Para isso, partiu-se de uma revisão de escopo (Sousa et al, 2020) desenvolvida anteriormente por duas coautoras deste estudo, que aborda sobre ferramentas para a seleção de pacientes para atendimento farmacêutico. Em seguida, foi realizada uma busca na literatura para identificar a revisão sistemática que seria comparada à revisão de Sousa e colaboradores (2020).…”

Section: Etapa 2 -Comparação E Análise Do Uso De Revisões De Escopo E Sistemática Na áRea Do Cuidado Ao Paciente Na Farmáciaunclassified

“…O artigo "Patient prioritization for pharmaceutical care in hospital: A systematic review of assessment tools" (Alshakrah, Steinke & Lewis, 2019) descreve as ferramentas de avaliação existentes usadas por farmácias hospitalares para avaliar a prioridade e/ou complexidade do paciente para ser elegível nos serviços clínicos em Farmácia. Em contrapartida, o artigo "Tools to prioritize outpatients for pharmaceutical service: A scoping review" (Sousa et al, 2020) retrata as ferramentas para a seleção de pacientes para atendimento clínico farmacêutico prestado em serviços de atenção à saúde primária e ambulatorial. Os autores do presente estudo avaliaram se as revisões selecionadas atenderam os itens dos checklist dos respectivos tipos de revisão, tal análise e comparação das revisões pode ser observada na Figura 3.…”

Section: Etapa 2 -Comparação E Análise Do Uso De Revisões De Escopo E Sistemática Na áRea Do Cuidado Ao Paciente Na Farmáciaunclassified

“…Em contrapartida, a revisão de escopo analisada "Tools to prioritize outpatients for pharmaceutical service: A scoping review" (Sousa et al, 2020) seguiu todas as orientações da diretriz PRISMA-ScR (Tricco et al, 2018) e do manual JBI para elaboração de revisões de escopo (Peters et al, 2020).…”

Section: Etapa 2 -Comparação E Análise Do Uso De Revisões De Escopo E Sistemática Na áRea Do Cuidado Ao Paciente Na Farmáciaunclassified

See 1 more Smart Citation

Comparação e análise do uso de revisão sistemática e revisão de escopo na área do cuidado ao paciente na Farmácia

Coelho

Rezende

Sousa

et al. 2021

RSD

Self Cite

View full text Add to dashboard Cite

O presente estudo tem como objetivo descrever e comparar dois métodos de revisão - sistemática e de escopo – além de analisar o uso destes métodos em estudos na área do cuidado ao paciente na farmácia. Os artigos utilizados para fundamentar este trabalho foram selecionados nas bases de dados: Google scholar, PubMed e Scielo. O estudo foi dividido em duas etapas: 1) Descrição e comparação de dois métodos de revisão da literatura: revisão sistemática e a revisão de escopo; 2) Análise e comparação do uso de revisões de escopo e sistemática na área de cuidado ao paciente na Farmácia. Constatou-se que os métodos para a elaboração das revisões estudadas seguem um processo sistemático e bem estruturado, mas se diferem quanto a alguns elementos metodológicos não observados na revisão de escopo, como a avaliação da qualidade dos estudos incluídos e análises estatísticas mais avançadas. A revisão sistemática analisada, ao contrário da revisão de escopo, não atendeu aos critérios propostos para a sua elaboração nas etapas de seleção e avaliação da qualidade dos estudos. Conclui-se que, embora as revisões se destinem a objetivos diferentes, ambas apresentam uma metodologia criteriosa. Associar corretamente a pergunta de pesquisa com o tipo de revisão é crucial para a condução do estudo.

show abstract

What Approaches Should be Used to Prioritize Pharmaceuticals and Personal Care Products for Research on Environmental and Human Health Exposure and Effects?

Guo

Iwata

et al. 2022

Enviro Toxic and Chemistry

View full text Add to dashboard Cite

Pharmaceuticals and personal care products (PPCPs) are released from multiple anthropogenic sources and thus have a ubiquitous presence in the environment. The environmental exposure and potential effects of PPCPs on biota and humans has aroused concern within the scientific community and the public. Risk assessments are commonly conducted to evaluate the likelihood of chemicals including PPCPs that pose health threats to organisms inhabiting various environmental compartments and humans. Because thousands of PPCPs are currently used, it is impractical to assess the environmental risk of all of them due to data limitations; in addition, new PPCPs are continually being produced. Prioritization approaches, based either on exposure, hazard, or risk, provide a possible means by which those PPCPs that are likely to pose the greatest risk to the environment are identified, thereby enabling more effective allocation of resources in environmental monitoring programs in specific geographical locations and ecotoxicological investigations. In the present review, the importance and current knowledge concerning PPCP occurrence and risk are discussed and priorities for future research are proposed, in terms of PPCP exposure (e.g., optimization of exposure modeling in freshwater ecosystems and more monitoring of PPCPs in the marine environment) or hazard (e.g., differential risk of PPCPs to lower vs. higher trophic level species and risks to human health). Recommended research questions for the next 10 years are also provided, which can be answered by future studies on prioritization of PPCPs. Environ Toxicol Chem 2022;00:1–14. © 2022 SETAC

show abstract

Tools to prioritize outpatients for pharmaceutical service: A scoping review

Cited by 11 publications

References 38 publications

External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drug‐related problems

External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drug‐related problems

Comparação e análise do uso de revisão sistemática e revisão de escopo na área do cuidado ao paciente na Farmácia

What Approaches Should be Used to Prioritize Pharmaceuticals and Personal Care Products for Research on Environmental and Human Health Exposure and Effects?

Contact Info

Product

Resources

About